Herantis Pharman vuosikertomus 2018 julkaistu
March 20, 2019 03:00 ET
|
Herantis Pharma Oyj
Herantis Pharman vuosikertomus 2018 julkaistu Herantis Pharma Oyj Yhtiötiedote 20.3.2019 kello 9:00 Herantis Pharma Oyj:n vuosikertomus vuodelta 2018 on julkaistu tänään. Vuosikertomus sisältää...
Herantis Pharma’s Annual Report 2018 published
March 20, 2019 03:00 ET
|
Herantis Pharma Oyj
Herantis Pharma’s Annual Report 2018 published Herantis Pharma Plc Company release 20 March 2019 at 9:00 am Herantis Pharma Plc’s Annual Report for the year 2018 has been published today. The Annual...
Laurantis Pharma and Ark Therapeutics Sign Manufacturing Agreement for Production of Lymfactin(TM) Investigational Treatment for Breast Cancer-Associated Lymphedema
October 15, 2012 08:00 ET
|
Laurantis Pharma Oy; Ark Therapeutics Group plc
LONDON and TURKU, FINLAND--(Marketwire - Oct 15, 2012) - Ark Therapeutics has been selected to manufacture and supply Lymfactin™ to Laurantis Pharma under a conditional agreement...
U.S. Patent Office Issues Patent to Laurantis for Cis-UCA as a Treatment for Bladder Cancer
October 09, 2012 08:00 ET
|
Laurantis Pharma OY
TURKU, FINLAND--(Marketwire - Oct 9, 2012) - The United States Patent and Trademark Office has allowed a patent application by Laurantis Pharma Oy (Laurantis) for the use of cis-urocanic acid...
Laurantis Pharma Completes Funding Round for Research Program
September 04, 2012 07:59 ET
|
Laurantis Pharma OY
BOSTON, MA and TURKU, FINLAND--(Marketwire - Sep 4, 2012) - Laurantis Pharma today announced successful completion of a funding round, which raised EUR 5.64 million (US$7.02 million). A...
U.S. Patent Office Allows Laurantis Application for Treatment of Skin Inflammation
August 01, 2012 08:00 ET
|
Laurantis Pharma Oy
TURKU, FINLAND--(Marketwire - Aug 1, 2012) - The United States Patent and Trademark Office has allowed a patent application by Laurantis Pharma Oy (Laurantis) as it pertains to the topical...
Research Team Discovers Four-Fold Improvement in Ability to Restore Lymphatic Function With Adenovirally-Delivered VEGF-C Gene Therapy After Lymph Node Transplant Surgery Compared to the Surgery Alone
March 06, 2012 14:30 ET
|
Laurantis Pharma OY
VENTURA, CA--(Marketwire - Mar 6, 2012) - Lymphedema Awareness Day was established to support the needs of patients with lymphedema and to raise awareness for the need to develop new treatment...